Biologic treatments in Takayasu's Arteritis : A comparative study of tumor necrosis factor inhibitors and tocilizumab
Copyright © 2021 Elsevier Inc. All rights reserved..
OBJECTIVE: To compare the treatment outcomes of TNF inhibitors and tocilizumab (TCZ) in patients with Takayasu arteritis.
METHODS: Takayasu arteritis patients who were refractory to conventional immunosuppressive (IS) drugs and received biologic treatment were included in this multicenter retrospective cohort study. Clinical, laboratory and imaging data during follow-up were recorded. Remission, glucocorticoid (GC) sparing effect, drug survival was compared between TNF inhibitor and TCZ treatments. Also, a subgroup matched comparison was performed between groups.
RESULTS: One hundred and eleven (F/M: 98/13) patients were enrolled. A total of 173 biologic treatment courses (77 infliximab, 49 TCZ, 33 adalimumab, 9 certolizumab, 3 rituximab, 1 ustekinumab and 1 anakinra) were given. Tocilizumab was chosen in 23 patients and TNF inhibitors were chosen in 88 patients as first-line biologic agent. Complete/partial remission rates between TCZ and TNF inhibitors were similar at 3rd month and at the end of the follow-up. GC dose decrease (≤4 mg) or discontinuation of GCs was achieved in a similar rate in both groups (TNF inhibitors vs TCZ: 78% vs 59%, p = 0.125). Drug survival rate was 56% in TNF inhibitors and 57% in TCZ group (p = 0.22). The use of concomitant conventional ISs did not affect the drug survival (HR =0.78, 95% CI =0.42-1.43, p = 0.42). The match analysis showed similar results between groups in terms of relapse, decrease in GC dose, surgery need and mortality.
CONCLUSION: The efficacy and safety outcomes and drug survival rates seem to be similar for TNF inhibitors and tocilizumab in patients with Takayasu arteritis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:51 |
|---|---|
| Enthalten in: |
Seminars in arthritis and rheumatism - 51(2021), 6 vom: 02. Dez., Seite 1224-1229 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alibaz-Oner, Fatma [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.03.2022 Date Revised 18.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.semarthrit.2021.09.010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332446743 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332446743 | ||
| 003 | DE-627 | ||
| 005 | 20231225215607.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.semarthrit.2021.09.010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1108.xml |
| 035 | |a (DE-627)NLM332446743 | ||
| 035 | |a (NLM)34706312 | ||
| 035 | |a (PII)S0049-0172(21)00184-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alibaz-Oner, Fatma |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Biologic treatments in Takayasu's Arteritis |b A comparative study of tumor necrosis factor inhibitors and tocilizumab |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.03.2022 | ||
| 500 | |a Date Revised 18.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Inc. All rights reserved. | ||
| 520 | |a OBJECTIVE: To compare the treatment outcomes of TNF inhibitors and tocilizumab (TCZ) in patients with Takayasu arteritis | ||
| 520 | |a METHODS: Takayasu arteritis patients who were refractory to conventional immunosuppressive (IS) drugs and received biologic treatment were included in this multicenter retrospective cohort study. Clinical, laboratory and imaging data during follow-up were recorded. Remission, glucocorticoid (GC) sparing effect, drug survival was compared between TNF inhibitor and TCZ treatments. Also, a subgroup matched comparison was performed between groups | ||
| 520 | |a RESULTS: One hundred and eleven (F/M: 98/13) patients were enrolled. A total of 173 biologic treatment courses (77 infliximab, 49 TCZ, 33 adalimumab, 9 certolizumab, 3 rituximab, 1 ustekinumab and 1 anakinra) were given. Tocilizumab was chosen in 23 patients and TNF inhibitors were chosen in 88 patients as first-line biologic agent. Complete/partial remission rates between TCZ and TNF inhibitors were similar at 3rd month and at the end of the follow-up. GC dose decrease (≤4 mg) or discontinuation of GCs was achieved in a similar rate in both groups (TNF inhibitors vs TCZ: 78% vs 59%, p = 0.125). Drug survival rate was 56% in TNF inhibitors and 57% in TCZ group (p = 0.22). The use of concomitant conventional ISs did not affect the drug survival (HR =0.78, 95% CI =0.42-1.43, p = 0.42). The match analysis showed similar results between groups in terms of relapse, decrease in GC dose, surgery need and mortality | ||
| 520 | |a CONCLUSION: The efficacy and safety outcomes and drug survival rates seem to be similar for TNF inhibitors and tocilizumab in patients with Takayasu arteritis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Biologic treatment | |
| 650 | 4 | |a Drug survival | |
| 650 | 4 | |a TNF inhibitor | |
| 650 | 4 | |a Takayasu arteritis | |
| 650 | 4 | |a Tocilizumab | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor Inhibitors |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 700 | 1 | |a Kaymaz-Tahra, Sema |e verfasserin |4 aut | |
| 700 | 1 | |a Bayındır, Özün |e verfasserin |4 aut | |
| 700 | 1 | |a Yazici, Ayten |e verfasserin |4 aut | |
| 700 | 1 | |a Ince, Burak |e verfasserin |4 aut | |
| 700 | 1 | |a Kalkan, Kübra |e verfasserin |4 aut | |
| 700 | 1 | |a Kanıtez, Nilüfer Alpay |e verfasserin |4 aut | |
| 700 | 1 | |a Kocaer, Sinem Burcu |e verfasserin |4 aut | |
| 700 | 1 | |a Yasar Bilge, Nazife Sule |e verfasserin |4 aut | |
| 700 | 1 | |a Omma, Ahmet |e verfasserin |4 aut | |
| 700 | 1 | |a Durak, Elif |e verfasserin |4 aut | |
| 700 | 1 | |a Ilgın, Can |e verfasserin |4 aut | |
| 700 | 1 | |a Akar, Servet |e verfasserin |4 aut | |
| 700 | 1 | |a Kaşifoğlu, Timuçin |e verfasserin |4 aut | |
| 700 | 1 | |a Önen, Fatoş |e verfasserin |4 aut | |
| 700 | 1 | |a Emmungil, Hakan |e verfasserin |4 aut | |
| 700 | 1 | |a İnanç, Murat |e verfasserin |4 aut | |
| 700 | 1 | |a Cefle, Ayşe |e verfasserin |4 aut | |
| 700 | 1 | |a Aksu, Kenan |e verfasserin |4 aut | |
| 700 | 1 | |a Keser, Gökhan |e verfasserin |4 aut | |
| 700 | 1 | |a Direskeneli, Haner |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Seminars in arthritis and rheumatism |d 1971 |g 51(2021), 6 vom: 02. Dez., Seite 1224-1229 |w (DE-627)NLM000215643 |x 1532-866X |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:2021 |g number:6 |g day:02 |g month:12 |g pages:1224-1229 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.semarthrit.2021.09.010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 2021 |e 6 |b 02 |c 12 |h 1224-1229 | ||